SlideShare a Scribd company logo
1 of 3
Download to read offline
GR% GR% GR%
JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14
- Ranbaxy SolusRanbaxy Solus 111101 715.22 824.35 100.00 100.00 15.26 2111.74 2431.32 100.00 100.00 15.13 4847.47 5465.66 100.00 100.00 12.75
- Ranbaxy SolusRanbaxy Solus 197906 37.09 44.68 5.19 5.42 20.48 108.08 131.85 5.12 5.42 21.99 248.67 291.85 5.13 5.34 17.36
GR% GR% GR%
JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14
- Ranbaxy Solus CareRanbaxy Solus Care 111101 1011.17 1144.10 100.00 100.00 13.15 2970.16 3352.21 100.00 100.00 12.86 6876.56 7543.66 100.00 100.00 9.70
- Ranbaxy Solus CareRanbaxy Solus Care 199710 20.96 25.48 2.07 2.23 21.59 59.21 73.46 1.99 2.19 24.07 136.87 165.65 1.99 2.20 21.03
RANKMKT/BRANDCORP_DIVISON - 2014 BRANDLAUNCH
MTHvalues in Mio's YTDvalues in Mio's
Val MS % Val MS % Val MS %
QTRvalues in Mio's
2MKT/BRANDCORP_DIVISON - 2014 BRANDLAUNCH
MTHvalues in Mio's YTDvalues in Mio's
Val MS % Val MS % Val MS %
QTRvalues in Mio's
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 3AS DIVALPROEX 131.7 23.1 57 100.0 (4.6) 655.7 24.1 54 100.0 (8.3) 1,669.8 23.7 59 100.0 (2.4)
4 DESVAL-ER - TAB--RBX (NCAS) 13.05 6.73 19 9.9 5.9 78.42 7.73 20 12.0 48.9 180.97 7.92 19 10.8 65.1
1 DEPAKOTE - TAB--SAV (NCAS) 30.64 8.85 35 23.3 (9.8) 154.73 8.53 36 23.6 (13.6) 409.73 7.68 44 24.5 5.1
2 DICORATE ER - TAB--SUN (NCAS) 33.58 15.33 22 25.5 (1.6) 154.78 14.74 21 23.6 (12.0) 387.62 14.52 22 23.2 1.4
3 DIVAA - TAB--INT (NCAS) 23.32 10.03 23 17.7 11.4 104.49 9.73 21 15.9 13.3 274.41 9.53 24 16.4 24.9
5 VALANCE - TAB--ABH (NCAS) 10.29 7.93 13 7.8 8.0 53.41 7.64 14 8.1 (3.9) 126.87 7.55 14 7.6 (16.9)
6 TREND XR - TAB--TRT (NCAS) 5.00 2.75 18 3.8 19.2 29.07 3.24 18 4.4 (18.8) 83.13 2.94 24 5.0 (38.7)
7 TIKOPREX - TAB--USV (NCAS) 3.60 3.40 11 2.7 (30.0) 14.44 3.04 9 2.2 (67.1) 51.60 3.36 13 3.1 (50.6)
8 VALKEM-OD - TAB--ALK (NCAS) 1.27 1.85 7 1.0 (72.2) 10.61 2.17 10 1.6 (44.4) 29.24 1.93 13 1.8 (32.5)
Rank Companies / Speacility
MTH YTD MAT
BU Solus & Solus Care Mkt
5 2 15 47 11 43 9 41
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 3AE CLOBAZAM 103.1 34.5 30 100.0 4.2 510.2 34.3 30 100.0 17.0 1,204.3 34.9 29 100.0 16.6
4 SOLZAM - TAB--RBX (NCAE) 8.47 7.73 11 8.2 303.9 40.50 7.71 11 7.9 247.9 79.85 7.20 9 6.6 131.8
1 FRISIUM - TAB--SAV (NCAE) 33.51 22.87 15 32.5 (6.7) 188.77 24.28 16 37.0 (2.6) 454.30 24.72 15 37.7 1.1
2 LOBAZAM - TAB--SUN (NCAE) 38.89 21.51 18 37.7 (10.1) 173.11 17.85 19 33.9 10.5 432.33 18.40 20 35.9 18.1
3 CLOBA - TAB--INT (NCAE) 17.09 9.24 18 16.6 51.1 72.23 10.02 14 14.2 42.5 152.68 10.16 13 12.7 17.8
5 CLOBATOR - TAB--TRT (NCAE) 1.95 3.17 6 1.9 (17.8) 9.52 2.54 7 1.9 32.5 31.74 3.42 8 2.6 45.1
6 CLOZAM - TAB--ABH (NCAE) 0.95 0.88 11 0.9 (51.5) 7.97 2.54 6 1.6 (2.7) 24.89 2.89 7 2.1 24.4
7 CLOBAKEM - TAB--ALK (NCAE) 0.39 0.37 11 0.4 (65.0) 9.29 1.92 10 1.8 113.2 12.89 1.24 9 1.1 59.4
8 CZAM - TAB--ETW (NCAE) 0.59 0.84 7 0.6 (48.7) 2.57 0.75 7 0.5 (46.6) 9.41 0.70 11 0.8 44.5
N 3AE CLOBAZAM Specility Neurologist Neuro Surgeon
Rank Companies / Speacility
MTH YTD MAT
Rx Trend in '000's Dr. Trendin '00's
BU Solus & Solus Care Mkt
5 2 15 47 11 43 9 41
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 3AE CLOBAZAM 103.1 34.5 30 100.0 4.2 510.2 34.3 30 100.0 17.0 1,204.3 34.9 29 100.0 16.6
4 SOLZAM - TAB--RBX (NCAE) 8.47 7.73 11 8.2 303.9 40.50 7.71 11 7.9 247.9 79.85 7.20 9 6.6 131.8
1 FRISIUM - TAB--SAV (NCAE) 33.51 22.87 15 32.5 (6.7) 188.77 24.28 16 37.0 (2.6) 454.30 24.72 15 37.7 1.1
2 LOBAZAM - TAB--SUN (NCAE) 38.89 21.51 18 37.7 (10.1) 173.11 17.85 19 33.9 10.5 432.33 18.40 20 35.9 18.1
3 CLOBA - TAB--INT (NCAE) 17.09 9.24 18 16.6 51.1 72.23 10.02 14 14.2 42.5 152.68 10.16 13 12.7 17.8
5 CLOBATOR - TAB--TRT (NCAE) 1.95 3.17 6 1.9 (17.8) 9.52 2.54 7 1.9 32.5 31.74 3.42 8 2.6 45.1
6 CLOZAM - TAB--ABH (NCAE) 0.95 0.88 11 0.9 (51.5) 7.97 2.54 6 1.6 (2.7) 24.89 2.89 7 2.1 24.4
7 CLOBAKEM - TAB--ALK (NCAE) 0.39 0.37 11 0.4 (65.0) 9.29 1.92 10 1.8 113.2 12.89 1.24 9 1.1 59.4
8 CZAM - TAB--ETW (NCAE) 0.59 0.84 7 0.6 (48.7) 2.57 0.75 7 0.5 (46.6) 9.41 0.70 11 0.8 44.5
N 3AE CLOBAZAM Specility Neurologist Neuro Surgeon
Rank Companies / Speacility
MTH YTD MAT
Rx Trend in '000's Dr. Trend in '00's
BU Solus & Solus Care Mkt
5 2 15 47 11 43 9 41
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 3AS DIVALPROEX 94.4 30.9 31 100.0 4.2 479.5 31.2 31 100.0 3.1 1,147.2 31.3 31 100.0 5.8
3 DESVAL-ER - TAB--RBX (NCAS) 13.56 8.97 15 14.4 (0.8) 75.00 8.92 17 15.6 25.2 179.27 10.78 14 15.6 36.3
1 DICORATE ER - TAB--SUN (NCAS) 22.24 12.48 18 23.6 (17.1) 113.38 12.89 18 23.6 (22.8) 289.82 12.20 20 25.3 (9.0)
2 VALANCE - TAB--ABH (NCAS) 16.68 13.79 12 17.7 17.2 84.50 13.13 13 17.6 31.6 187.18 13.02 12 16.3 15.6
4 DIVAA - TAB--INT (NCAS) 9.43 8.97 11 10.0 (3.3) 48.09 12.05 8 10.0 (2.9) 136.06 11.51 10 11.9 0.7
5 TIKOPREX - TAB--USV (NCAS) 5.93 0.90 66 6.3 115.5 26.09 1.46 36 5.4 48.6 54.55 1.34 34 4.8 31.1
6 DIVALEP ER - TAB--ABH (NCAS) 5.27 0.86 61 5.6 43.3 21.19 0.71 60 4.4 1.7 47.37 0.62 64 4.1 82.7
7 DAYO-OD - TAB--LUP (NCAS) 2.29 3.39 7 2.4 (22.0) 20.76 4.25 10 4.3 26.7 44.02 3.96 9 3.8 25.5
8 DIVALIN-OD - TAB--MKI (NCAS) 2.14 0.54 40 2.3 (18.9) 13.94 0.56 50 2.9 4.9 36.14 0.92 33 3.2 19.8
N 3AS DIVALPROEX Specility Neurologist Neuro Surgeon
Rank Companies / Speacility
MTH YTD MAT
BU Solus & Solus Care Mkt
5 2 15 47 11 43 9 41
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 3AT LEVETIRACETAM 146.0 41.4 35 100.0 10.0 698.9 42.2 33 100.0 11.4 1,593.9 40.5 33 100.0 16.2
6 LEVROXA - TAB--RBX (NCAT) 3.59 4.55 8 2.5 (10.1) 24.55 5.32 9 3.5 1.4 68.74 5.68 10 4.3 92.9
32 LEVROXA - INJ--RBX (NCAT) 0.00 0.00 0.0 0.37 0.21 3 0.1 0.42 0.12 3 0.0
1 LEVIPIL - TAB--SUN (NCAT) 43.18 27.30 16 29.6 3.8 194.15 27.86 14 27.8 (3.6) 473.92 26.79 15 29.7 9.7
2 LEVESAM - TAB--ABH (NCAT) 18.03 8.88 20 12.4 (34.3) 93.16 10.41 18 13.3 (6.2) 231.90 10.07 19 14.5 23.1
3 LEVERA - TAB--INT (NCAT) 17.38 19.27 9 11.9 (1.9) 87.85 17.54 10 12.6 (0.6) 197.68 17.11 10 12.4 0.3
4 EPILIVE - TAB--LUP (NCAT) 22.04 11.16 20 15.1 188.5 96.38 10.67 18 13.8 155.2 169.49 9.33 15 10.6 62.5
5 LEVACETAM - TAB--MCL (NCAT) 8.42 4.59 18 5.8 17.0 36.86 3.83 19 5.3 (16.4) 91.17 4.16 18 5.7 (0.3)
7 TORLEVA - TAB--TRT (NCAT) 5.62 10.16 6 3.9 (3.6) 29.09 9.09 6 4.2 (4.5) 64.20 7.32 7 4.0 (20.6)
N 3AT LEVETIRACETAM Specility Neurologist Neuro Surgeon
Rank Companies / Speacility
MTH YTD MAT
Rx Trend in '000's Dr. Trendin '00's
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 6AD SERTRALINE 22.3 18.0 12 100.0 1.1 103.6 15.9 13 100.0 10.8 222.4 14.6 13 100.0 2.0
3 SERLIFT - TAB--RBX (NFAD) 2.18 3.53 6 9.8 (48.1) 15.06 3.70 8 14.5 32.0 44.87 3.89 10 20.2 48.9
1 SERTA - TAB--UCL (NFAD) 6.27 8.08 8 28.1 (11.5) 35.54 6.93 10 34.3 9.7 72.54 6.48 9 32.6 8.9
2 DAXID - TAB--PFZ (NFAD) 7.91 4.53 17 35.4 14.5 26.79 5.27 10 25.8 (20.6) 55.70 5.26 9 25.0 (31.9)
4 ZOSERT - TAB--SUN (NFAD) 2.12 3.90 5 9.5 3.1 8.24 2.78 6 8.0 19.7 15.59 1.97 7 7.0 (5.8)
5 SERENE - TAB--APX (NFAD) 1.90 1.15 16 8.5 8.77 1.09 16 8.5 713.9 14.84 0.82 15 6.7 1,276.3
6 SERTIN - TAB--TAS (NFAD) 0.94 0.29 32 4.2 39.9 5.53 0.33 34 5.3 83.7 9.69 0.31 26 4.4 (0.4)
7 INOSERT - TAB--IPC (NFAD) 0.62 2.07 3 2.8 1.22 0.83 3 1.2 181.7 2.90 0.81 3 1.3 51.3
8 S R T - TAB--SHI (NFAD) 0.11 0.30 4 0.5 (70.2) 0.87 0.27 6 0.8 (40.5) 2.04 0.38 5 0.9 5.7
Rank Companies / Speacility
MTH YTD MAT
BU Solus & Solus Care Mkt
5 2 15 47 11 43 9 41
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 6AD SERTRALINE 74.9 17.9 42 100.0 7.3 350.3 18.5 38 100.0 8.9 831.2 17.6 39 100.0 14.8
4 SERLIFT - TAB--RBX (NFAD) 7.67 3.77 20 10.2 37.6 40.57 4.59 18 11.6 181.4 92.15 4.47 17 11.1 251.0
1 SERTA - TAB--UCL (NFAD) 33.01 11.30 29 44.1 24.7 154.39 11.30 27 44.1 1.8 352.42 10.26 29 42.4 4.4
2 DAXID - TAB--PFZ (NFAD) 12.27 6.70 18 16.4 (16.1) 61.15 7.99 15 17.5 0.7 153.95 7.81 16 18.5 12.5
3 ZOSERT - TAB--SUN (NFAD) 9.20 5.25 18 12.3 (13.1) 35.32 5.06 14 10.1 14.4 95.75 4.94 16 11.5 54.9
5 SERENATA - TAB--TRT (NFAD) 6.87 2.54 27 9.2 47.8 21.68 2.46 18 6.2 (9.3) 43.52 2.24 16 5.2 (34.4)
6 SERTIMA - TAB--INT (NFAD) 1.07 0.80 13 1.4 (58.6) 7.78 1.18 13 2.2 (49.8) 26.37 1.37 16 3.2 (31.2)
7 TRALIN - TAB--ALK (NFAD) 0.77 1.63 5 1.0 17.0 10.83 1.63 13 3.1 341.5 25.53 1.41 15 3.1 236.5
8 DEPSERT - TAB--REL (NFAD) 1.86 1.86 10 2.5 123.0 8.37 1.48 11 2.4 41.5 14.35 1.24 10 1.7 (28.0)
N 6AD SERTRALINE Specility Psychiatrist
Rank Companies / Speacility
MTH YTD MAT
BU Solus & Solus Care Mkt
5 2 15 47 11 43 9 41
Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth %
N 3AS DIVALPROEX 131.7 23.1 57 100.0 (4.6) 655.7 24.1 54 100.0 (8.3) 1,669.8 23.7 59 100.0 (2.4)
4 DESVAL-ER - TAB--RBX (NCAS) 13.05 6.73 19 9.9 5.9 78.42 7.73 20 12.0 48.9 180.97 7.92 19 10.8 65.1
1 DEPAKOTE - TAB--SAV (NCAS) 30.64 8.85 35 23.3 (9.8) 154.73 8.53 36 23.6 (13.6) 409.73 7.68 44 24.5 5.1
2 DICORATE ER - TAB--SUN (NCAS) 33.58 15.33 22 25.5 (1.6) 154.78 14.74 21 23.6 (12.0) 387.62 14.52 22 23.2 1.4
3 DIVAA - TAB--INT (NCAS) 23.32 10.03 23 17.7 11.4 104.49 9.73 21 15.9 13.3 274.41 9.53 24 16.4 24.9
5 VALANCE - TAB--ABH (NCAS) 10.29 7.93 13 7.8 8.0 53.41 7.64 14 8.1 (3.9) 126.87 7.55 14 7.6 (16.9)
6 TREND XR - TAB--TRT (NCAS) 5.00 2.75 18 3.8 19.2 29.07 3.24 18 4.4 (18.8) 83.13 2.94 24 5.0 (38.7)
7 TIKOPREX - TAB--USV (NCAS) 3.60 3.40 11 2.7 (30.0) 14.44 3.04 9 2.2 (67.1) 51.60 3.36 13 3.1 (50.6)
8 VALKEM-OD - TAB--ALK (NCAS) 1.27 1.85 7 1.0 (72.2) 10.61 2.17 10 1.6 (44.4) 29.24 1.93 13 1.8 (32.5)
N 3AS DIVALPROEX Specility Psychiatrist
Rank Companies / Speacility
MTH YTD MAT

More Related Content

Similar to Solus & Solus Care Monthly Market Report

Seattle public companies
Seattle public companiesSeattle public companies
Seattle public companies~Eric Principe
 
(597922903) trabajo sobre aguas residuales 1
(597922903) trabajo sobre aguas residuales 1(597922903) trabajo sobre aguas residuales 1
(597922903) trabajo sobre aguas residuales 1Juliana Hincapié Rojo
 
Template Hemodinamik CVC.pptx
Template Hemodinamik CVC.pptxTemplate Hemodinamik CVC.pptx
Template Hemodinamik CVC.pptxSebastianChandra3
 
IDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR System
IDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR SystemIDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR System
IDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR SystemThermo Fisher Scientific
 
St st pipe_pressure_rating_charts_rev_sep_2010
St st pipe_pressure_rating_charts_rev_sep_2010St st pipe_pressure_rating_charts_rev_sep_2010
St st pipe_pressure_rating_charts_rev_sep_2010setyopermadi
 
SPECTRAL-BASED FATIGUE ASSESSMENT OF FSO
SPECTRAL-BASED FATIGUE ASSESSMENT OF FSOSPECTRAL-BASED FATIGUE ASSESSMENT OF FSO
SPECTRAL-BASED FATIGUE ASSESSMENT OF FSOSUMARDIONO .
 
Xevo TQ-XS Data: Quantifying Mid-size Proteins
Xevo TQ-XS Data: Quantifying Mid-size ProteinsXevo TQ-XS Data: Quantifying Mid-size Proteins
Xevo TQ-XS Data: Quantifying Mid-size ProteinsLarry Hines
 
Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...
Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...
Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...Thermo Fisher Scientific
 
J. Thomas & Co. - PY GRP PPT
J. Thomas & Co. - PY GRP PPTJ. Thomas & Co. - PY GRP PPT
J. Thomas & Co. - PY GRP PPTKoshy Panicker
 
2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...
2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...
2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...Komandur Sunder Raj, P.E.
 
Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...
Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...
Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...EuFMD
 
OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...
OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...
OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...EuFMD
 

Similar to Solus & Solus Care Monthly Market Report (20)

Seattle public companies
Seattle public companiesSeattle public companies
Seattle public companies
 
(597922903) trabajo sobre aguas residuales 1
(597922903) trabajo sobre aguas residuales 1(597922903) trabajo sobre aguas residuales 1
(597922903) trabajo sobre aguas residuales 1
 
Template Hemodinamik CVC.pptx
Template Hemodinamik CVC.pptxTemplate Hemodinamik CVC.pptx
Template Hemodinamik CVC.pptx
 
IDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR System
IDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR SystemIDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR System
IDNADEX: Improving DNA Data Exchange Validation Studies of a Global STR System
 
Indices 19 may2014060418
Indices 19 may2014060418Indices 19 may2014060418
Indices 19 may2014060418
 
St st pipe_pressure_rating_charts_rev_sep_2010
St st pipe_pressure_rating_charts_rev_sep_2010St st pipe_pressure_rating_charts_rev_sep_2010
St st pipe_pressure_rating_charts_rev_sep_2010
 
SPECTRAL-BASED FATIGUE ASSESSMENT OF FSO
SPECTRAL-BASED FATIGUE ASSESSMENT OF FSOSPECTRAL-BASED FATIGUE ASSESSMENT OF FSO
SPECTRAL-BASED FATIGUE ASSESSMENT OF FSO
 
PSpice Model of Solar cell
PSpice Model of Solar cell PSpice Model of Solar cell
PSpice Model of Solar cell
 
Indices 10 may2013060757
Indices 10 may2013060757Indices 10 may2013060757
Indices 10 may2013060757
 
Xevo TQ-XS Data: Quantifying Mid-size Proteins
Xevo TQ-XS Data: Quantifying Mid-size ProteinsXevo TQ-XS Data: Quantifying Mid-size Proteins
Xevo TQ-XS Data: Quantifying Mid-size Proteins
 
Indices 05 mar2013052614
Indices 05 mar2013052614Indices 05 mar2013052614
Indices 05 mar2013052614
 
Indices 04 mar2013063301
Indices 04 mar2013063301Indices 04 mar2013063301
Indices 04 mar2013063301
 
Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...
Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...
Development of a Multi-Variant Frequency Ladder™ for Next Generation Sequenci...
 
J. Thomas & Co. - PY GRP PPT
J. Thomas & Co. - PY GRP PPTJ. Thomas & Co. - PY GRP PPT
J. Thomas & Co. - PY GRP PPT
 
08 Bernat aimradial20170921 Radial patency
08 Bernat aimradial20170921 Radial patency08 Bernat aimradial20170921 Radial patency
08 Bernat aimradial20170921 Radial patency
 
Indices 08 apr2013045729
Indices 08 apr2013045729Indices 08 apr2013045729
Indices 08 apr2013045729
 
Chromatography: Meeting the Challenges of EU regulations with up-to-date Conf...
Chromatography: Meeting the Challenges of EU regulations with up-to-date Conf...Chromatography: Meeting the Challenges of EU regulations with up-to-date Conf...
Chromatography: Meeting the Challenges of EU regulations with up-to-date Conf...
 
2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...
2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...
2006 ASME Power Conference Last Stage Performance Considerations in LP Turbin...
 
Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...
Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...
Multiplex Real-Time RT-PCR for Detection of FMDV, Rift Valley Fever Virus and...
 
OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...
OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...
OS18 - 10.a.1 Multiplex Real-time RT-PCR for detection of FMDV, Rift Valley f...
 

Solus & Solus Care Monthly Market Report

  • 1. GR% GR% GR% JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 - Ranbaxy SolusRanbaxy Solus 111101 715.22 824.35 100.00 100.00 15.26 2111.74 2431.32 100.00 100.00 15.13 4847.47 5465.66 100.00 100.00 12.75 - Ranbaxy SolusRanbaxy Solus 197906 37.09 44.68 5.19 5.42 20.48 108.08 131.85 5.12 5.42 21.99 248.67 291.85 5.13 5.34 17.36 GR% GR% GR% JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 JUL'13 JUL'14 JUL'13 JUL'14 JUL'14 - Ranbaxy Solus CareRanbaxy Solus Care 111101 1011.17 1144.10 100.00 100.00 13.15 2970.16 3352.21 100.00 100.00 12.86 6876.56 7543.66 100.00 100.00 9.70 - Ranbaxy Solus CareRanbaxy Solus Care 199710 20.96 25.48 2.07 2.23 21.59 59.21 73.46 1.99 2.19 24.07 136.87 165.65 1.99 2.20 21.03 RANKMKT/BRANDCORP_DIVISON - 2014 BRANDLAUNCH MTHvalues in Mio's YTDvalues in Mio's Val MS % Val MS % Val MS % QTRvalues in Mio's 2MKT/BRANDCORP_DIVISON - 2014 BRANDLAUNCH MTHvalues in Mio's YTDvalues in Mio's Val MS % Val MS % Val MS % QTRvalues in Mio's Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 3AS DIVALPROEX 131.7 23.1 57 100.0 (4.6) 655.7 24.1 54 100.0 (8.3) 1,669.8 23.7 59 100.0 (2.4) 4 DESVAL-ER - TAB--RBX (NCAS) 13.05 6.73 19 9.9 5.9 78.42 7.73 20 12.0 48.9 180.97 7.92 19 10.8 65.1 1 DEPAKOTE - TAB--SAV (NCAS) 30.64 8.85 35 23.3 (9.8) 154.73 8.53 36 23.6 (13.6) 409.73 7.68 44 24.5 5.1 2 DICORATE ER - TAB--SUN (NCAS) 33.58 15.33 22 25.5 (1.6) 154.78 14.74 21 23.6 (12.0) 387.62 14.52 22 23.2 1.4 3 DIVAA - TAB--INT (NCAS) 23.32 10.03 23 17.7 11.4 104.49 9.73 21 15.9 13.3 274.41 9.53 24 16.4 24.9 5 VALANCE - TAB--ABH (NCAS) 10.29 7.93 13 7.8 8.0 53.41 7.64 14 8.1 (3.9) 126.87 7.55 14 7.6 (16.9) 6 TREND XR - TAB--TRT (NCAS) 5.00 2.75 18 3.8 19.2 29.07 3.24 18 4.4 (18.8) 83.13 2.94 24 5.0 (38.7) 7 TIKOPREX - TAB--USV (NCAS) 3.60 3.40 11 2.7 (30.0) 14.44 3.04 9 2.2 (67.1) 51.60 3.36 13 3.1 (50.6) 8 VALKEM-OD - TAB--ALK (NCAS) 1.27 1.85 7 1.0 (72.2) 10.61 2.17 10 1.6 (44.4) 29.24 1.93 13 1.8 (32.5) Rank Companies / Speacility MTH YTD MAT BU Solus & Solus Care Mkt 5 2 15 47 11 43 9 41 Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 3AE CLOBAZAM 103.1 34.5 30 100.0 4.2 510.2 34.3 30 100.0 17.0 1,204.3 34.9 29 100.0 16.6 4 SOLZAM - TAB--RBX (NCAE) 8.47 7.73 11 8.2 303.9 40.50 7.71 11 7.9 247.9 79.85 7.20 9 6.6 131.8 1 FRISIUM - TAB--SAV (NCAE) 33.51 22.87 15 32.5 (6.7) 188.77 24.28 16 37.0 (2.6) 454.30 24.72 15 37.7 1.1 2 LOBAZAM - TAB--SUN (NCAE) 38.89 21.51 18 37.7 (10.1) 173.11 17.85 19 33.9 10.5 432.33 18.40 20 35.9 18.1 3 CLOBA - TAB--INT (NCAE) 17.09 9.24 18 16.6 51.1 72.23 10.02 14 14.2 42.5 152.68 10.16 13 12.7 17.8 5 CLOBATOR - TAB--TRT (NCAE) 1.95 3.17 6 1.9 (17.8) 9.52 2.54 7 1.9 32.5 31.74 3.42 8 2.6 45.1 6 CLOZAM - TAB--ABH (NCAE) 0.95 0.88 11 0.9 (51.5) 7.97 2.54 6 1.6 (2.7) 24.89 2.89 7 2.1 24.4 7 CLOBAKEM - TAB--ALK (NCAE) 0.39 0.37 11 0.4 (65.0) 9.29 1.92 10 1.8 113.2 12.89 1.24 9 1.1 59.4 8 CZAM - TAB--ETW (NCAE) 0.59 0.84 7 0.6 (48.7) 2.57 0.75 7 0.5 (46.6) 9.41 0.70 11 0.8 44.5 N 3AE CLOBAZAM Specility Neurologist Neuro Surgeon Rank Companies / Speacility MTH YTD MAT Rx Trend in '000's Dr. Trendin '00's BU Solus & Solus Care Mkt 5 2 15 47 11 43 9 41 Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 3AE CLOBAZAM 103.1 34.5 30 100.0 4.2 510.2 34.3 30 100.0 17.0 1,204.3 34.9 29 100.0 16.6 4 SOLZAM - TAB--RBX (NCAE) 8.47 7.73 11 8.2 303.9 40.50 7.71 11 7.9 247.9 79.85 7.20 9 6.6 131.8 1 FRISIUM - TAB--SAV (NCAE) 33.51 22.87 15 32.5 (6.7) 188.77 24.28 16 37.0 (2.6) 454.30 24.72 15 37.7 1.1 2 LOBAZAM - TAB--SUN (NCAE) 38.89 21.51 18 37.7 (10.1) 173.11 17.85 19 33.9 10.5 432.33 18.40 20 35.9 18.1 3 CLOBA - TAB--INT (NCAE) 17.09 9.24 18 16.6 51.1 72.23 10.02 14 14.2 42.5 152.68 10.16 13 12.7 17.8 5 CLOBATOR - TAB--TRT (NCAE) 1.95 3.17 6 1.9 (17.8) 9.52 2.54 7 1.9 32.5 31.74 3.42 8 2.6 45.1 6 CLOZAM - TAB--ABH (NCAE) 0.95 0.88 11 0.9 (51.5) 7.97 2.54 6 1.6 (2.7) 24.89 2.89 7 2.1 24.4 7 CLOBAKEM - TAB--ALK (NCAE) 0.39 0.37 11 0.4 (65.0) 9.29 1.92 10 1.8 113.2 12.89 1.24 9 1.1 59.4 8 CZAM - TAB--ETW (NCAE) 0.59 0.84 7 0.6 (48.7) 2.57 0.75 7 0.5 (46.6) 9.41 0.70 11 0.8 44.5 N 3AE CLOBAZAM Specility Neurologist Neuro Surgeon Rank Companies / Speacility MTH YTD MAT Rx Trend in '000's Dr. Trend in '00's
  • 2. BU Solus & Solus Care Mkt 5 2 15 47 11 43 9 41 Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 3AS DIVALPROEX 94.4 30.9 31 100.0 4.2 479.5 31.2 31 100.0 3.1 1,147.2 31.3 31 100.0 5.8 3 DESVAL-ER - TAB--RBX (NCAS) 13.56 8.97 15 14.4 (0.8) 75.00 8.92 17 15.6 25.2 179.27 10.78 14 15.6 36.3 1 DICORATE ER - TAB--SUN (NCAS) 22.24 12.48 18 23.6 (17.1) 113.38 12.89 18 23.6 (22.8) 289.82 12.20 20 25.3 (9.0) 2 VALANCE - TAB--ABH (NCAS) 16.68 13.79 12 17.7 17.2 84.50 13.13 13 17.6 31.6 187.18 13.02 12 16.3 15.6 4 DIVAA - TAB--INT (NCAS) 9.43 8.97 11 10.0 (3.3) 48.09 12.05 8 10.0 (2.9) 136.06 11.51 10 11.9 0.7 5 TIKOPREX - TAB--USV (NCAS) 5.93 0.90 66 6.3 115.5 26.09 1.46 36 5.4 48.6 54.55 1.34 34 4.8 31.1 6 DIVALEP ER - TAB--ABH (NCAS) 5.27 0.86 61 5.6 43.3 21.19 0.71 60 4.4 1.7 47.37 0.62 64 4.1 82.7 7 DAYO-OD - TAB--LUP (NCAS) 2.29 3.39 7 2.4 (22.0) 20.76 4.25 10 4.3 26.7 44.02 3.96 9 3.8 25.5 8 DIVALIN-OD - TAB--MKI (NCAS) 2.14 0.54 40 2.3 (18.9) 13.94 0.56 50 2.9 4.9 36.14 0.92 33 3.2 19.8 N 3AS DIVALPROEX Specility Neurologist Neuro Surgeon Rank Companies / Speacility MTH YTD MAT BU Solus & Solus Care Mkt 5 2 15 47 11 43 9 41 Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 3AT LEVETIRACETAM 146.0 41.4 35 100.0 10.0 698.9 42.2 33 100.0 11.4 1,593.9 40.5 33 100.0 16.2 6 LEVROXA - TAB--RBX (NCAT) 3.59 4.55 8 2.5 (10.1) 24.55 5.32 9 3.5 1.4 68.74 5.68 10 4.3 92.9 32 LEVROXA - INJ--RBX (NCAT) 0.00 0.00 0.0 0.37 0.21 3 0.1 0.42 0.12 3 0.0 1 LEVIPIL - TAB--SUN (NCAT) 43.18 27.30 16 29.6 3.8 194.15 27.86 14 27.8 (3.6) 473.92 26.79 15 29.7 9.7 2 LEVESAM - TAB--ABH (NCAT) 18.03 8.88 20 12.4 (34.3) 93.16 10.41 18 13.3 (6.2) 231.90 10.07 19 14.5 23.1 3 LEVERA - TAB--INT (NCAT) 17.38 19.27 9 11.9 (1.9) 87.85 17.54 10 12.6 (0.6) 197.68 17.11 10 12.4 0.3 4 EPILIVE - TAB--LUP (NCAT) 22.04 11.16 20 15.1 188.5 96.38 10.67 18 13.8 155.2 169.49 9.33 15 10.6 62.5 5 LEVACETAM - TAB--MCL (NCAT) 8.42 4.59 18 5.8 17.0 36.86 3.83 19 5.3 (16.4) 91.17 4.16 18 5.7 (0.3) 7 TORLEVA - TAB--TRT (NCAT) 5.62 10.16 6 3.9 (3.6) 29.09 9.09 6 4.2 (4.5) 64.20 7.32 7 4.0 (20.6) N 3AT LEVETIRACETAM Specility Neurologist Neuro Surgeon Rank Companies / Speacility MTH YTD MAT Rx Trend in '000's Dr. Trendin '00's Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 6AD SERTRALINE 22.3 18.0 12 100.0 1.1 103.6 15.9 13 100.0 10.8 222.4 14.6 13 100.0 2.0 3 SERLIFT - TAB--RBX (NFAD) 2.18 3.53 6 9.8 (48.1) 15.06 3.70 8 14.5 32.0 44.87 3.89 10 20.2 48.9 1 SERTA - TAB--UCL (NFAD) 6.27 8.08 8 28.1 (11.5) 35.54 6.93 10 34.3 9.7 72.54 6.48 9 32.6 8.9 2 DAXID - TAB--PFZ (NFAD) 7.91 4.53 17 35.4 14.5 26.79 5.27 10 25.8 (20.6) 55.70 5.26 9 25.0 (31.9) 4 ZOSERT - TAB--SUN (NFAD) 2.12 3.90 5 9.5 3.1 8.24 2.78 6 8.0 19.7 15.59 1.97 7 7.0 (5.8) 5 SERENE - TAB--APX (NFAD) 1.90 1.15 16 8.5 8.77 1.09 16 8.5 713.9 14.84 0.82 15 6.7 1,276.3 6 SERTIN - TAB--TAS (NFAD) 0.94 0.29 32 4.2 39.9 5.53 0.33 34 5.3 83.7 9.69 0.31 26 4.4 (0.4) 7 INOSERT - TAB--IPC (NFAD) 0.62 2.07 3 2.8 1.22 0.83 3 1.2 181.7 2.90 0.81 3 1.3 51.3 8 S R T - TAB--SHI (NFAD) 0.11 0.30 4 0.5 (70.2) 0.87 0.27 6 0.8 (40.5) 2.04 0.38 5 0.9 5.7 Rank Companies / Speacility MTH YTD MAT
  • 3. BU Solus & Solus Care Mkt 5 2 15 47 11 43 9 41 Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 6AD SERTRALINE 74.9 17.9 42 100.0 7.3 350.3 18.5 38 100.0 8.9 831.2 17.6 39 100.0 14.8 4 SERLIFT - TAB--RBX (NFAD) 7.67 3.77 20 10.2 37.6 40.57 4.59 18 11.6 181.4 92.15 4.47 17 11.1 251.0 1 SERTA - TAB--UCL (NFAD) 33.01 11.30 29 44.1 24.7 154.39 11.30 27 44.1 1.8 352.42 10.26 29 42.4 4.4 2 DAXID - TAB--PFZ (NFAD) 12.27 6.70 18 16.4 (16.1) 61.15 7.99 15 17.5 0.7 153.95 7.81 16 18.5 12.5 3 ZOSERT - TAB--SUN (NFAD) 9.20 5.25 18 12.3 (13.1) 35.32 5.06 14 10.1 14.4 95.75 4.94 16 11.5 54.9 5 SERENATA - TAB--TRT (NFAD) 6.87 2.54 27 9.2 47.8 21.68 2.46 18 6.2 (9.3) 43.52 2.24 16 5.2 (34.4) 6 SERTIMA - TAB--INT (NFAD) 1.07 0.80 13 1.4 (58.6) 7.78 1.18 13 2.2 (49.8) 26.37 1.37 16 3.2 (31.2) 7 TRALIN - TAB--ALK (NFAD) 0.77 1.63 5 1.0 17.0 10.83 1.63 13 3.1 341.5 25.53 1.41 15 3.1 236.5 8 DEPSERT - TAB--REL (NFAD) 1.86 1.86 10 2.5 123.0 8.37 1.48 11 2.4 41.5 14.35 1.24 10 1.7 (28.0) N 6AD SERTRALINE Specility Psychiatrist Rank Companies / Speacility MTH YTD MAT BU Solus & Solus Care Mkt 5 2 15 47 11 43 9 41 Rx '000's Dr. '00's P/D/M Rx MS% Rx Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % Rx '000's Dr. '00's P/D/M Rx MS% Gth % N 3AS DIVALPROEX 131.7 23.1 57 100.0 (4.6) 655.7 24.1 54 100.0 (8.3) 1,669.8 23.7 59 100.0 (2.4) 4 DESVAL-ER - TAB--RBX (NCAS) 13.05 6.73 19 9.9 5.9 78.42 7.73 20 12.0 48.9 180.97 7.92 19 10.8 65.1 1 DEPAKOTE - TAB--SAV (NCAS) 30.64 8.85 35 23.3 (9.8) 154.73 8.53 36 23.6 (13.6) 409.73 7.68 44 24.5 5.1 2 DICORATE ER - TAB--SUN (NCAS) 33.58 15.33 22 25.5 (1.6) 154.78 14.74 21 23.6 (12.0) 387.62 14.52 22 23.2 1.4 3 DIVAA - TAB--INT (NCAS) 23.32 10.03 23 17.7 11.4 104.49 9.73 21 15.9 13.3 274.41 9.53 24 16.4 24.9 5 VALANCE - TAB--ABH (NCAS) 10.29 7.93 13 7.8 8.0 53.41 7.64 14 8.1 (3.9) 126.87 7.55 14 7.6 (16.9) 6 TREND XR - TAB--TRT (NCAS) 5.00 2.75 18 3.8 19.2 29.07 3.24 18 4.4 (18.8) 83.13 2.94 24 5.0 (38.7) 7 TIKOPREX - TAB--USV (NCAS) 3.60 3.40 11 2.7 (30.0) 14.44 3.04 9 2.2 (67.1) 51.60 3.36 13 3.1 (50.6) 8 VALKEM-OD - TAB--ALK (NCAS) 1.27 1.85 7 1.0 (72.2) 10.61 2.17 10 1.6 (44.4) 29.24 1.93 13 1.8 (32.5) N 3AS DIVALPROEX Specility Psychiatrist Rank Companies / Speacility MTH YTD MAT